ENDO 2026 Highlight: After 70 Years, a New Way to Treat Congenital Adrenal Hyperplasia

We welcome  Dr. Richard Auchus as he discusses congenital adrenal hyperplasia (CAH), its current treatments, and introduces a groundbreaking drug, Crenessity (crinecerfont), that could revolutionize management of the condition. Dr. Auchus explains how Crenessity (crinecerfont), the first drug of its kind, is easing the steroid burden for CAH patients and reshaping how the disease is managed. Learn about the latest advances in endocrinology and how new therapies are improving patient outcomes.

What he talks about this engaging interview:

  • Congenital adrenal hyperplasia (CAH) and its genetic basis
  • Current treatment challenges for CAH and long-term health risks
  • Introduction of crinesity, a new drug targeting the HPA axis
  • Mechanism of action of crinesity as a corticotropin releasing factor antagonist
  • Benefits of new therapy: reduced glucocorticoid use, improved patient outcomes
  • Future directions in CAH treatment: additional drugs targeting ACTH and adrenal response
  • Impact of new treatments on quality of life and disease management
  • The importance of early diagnosis and ongoing management in CAH

 

And the key takeaways:

  • Crinesity is a first-in-class drug that blocks the corticotropin releasing factor receptor, reducing ACTH production.
  • Using crinesity can lower the required dose of glucocorticoids, decreasing side effects like osteoporosis and cardiovascular risks.
  • New therapies are making it easier to manage CAH, potentially restoring closer to normal physiology.
  • Reducing glucocorticoid exposure can lead to weight loss, better insulin sensitivity, and improved bone health.
  • The development of drugs targeting the ACTH receptor and neutralizing ACTH itself represents a promising future for CAH treatment.

More information on Congenital Adrenal Hyperplasia at the Cares Foundation

© 2026, J D Faccinetti. All rights reserved.

Leave a Reply

Your email address will not be published. Required fields are marked *